Ernest Bognar

446 total citations
23 papers, 187 citations indexed

About

Ernest Bognar is a scholar working on Oncology, Immunology and Reproductive Medicine. According to data from OpenAlex, Ernest Bognar has authored 23 papers receiving a total of 187 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Immunology and 7 papers in Reproductive Medicine. Recurrent topics in Ernest Bognar's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (8 papers) and PARP inhibition in cancer therapy (8 papers). Ernest Bognar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (8 papers) and PARP inhibition in cancer therapy (8 papers). Ernest Bognar collaborates with scholars based in United States. Ernest Bognar's co-authors include John Nemunaitis, Laura Stanbery, Luisa Manning, Phylicia Aaron, Gladice Wallraven, Staci Horvath, Rodney P. Rocconi, Robert L. Coleman, Bradley J. Monk and Minal Barve and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Ernest Bognar

21 papers receiving 181 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ernest Bognar United States	9	155	92	53	48	21	23	187
Staci Horvath United States	10	174 1.1×	107 1.2×	89 1.7×	37 0.8×	39 1.9×	14	248
E. Hitt Nichols United States	3	231 1.5×	96 1.0×	83 1.6×	91 1.9×	19 0.9×	5	267
Luisa Manning United States	12	199 1.3×	117 1.3×	111 2.1×	71 1.5×	40 1.9×	28	299
Hao Ran United States	3	105 0.7×	41 0.4×	93 1.8×	112 2.3×	71 3.4×	4	236
Gladice Wallraven United States	11	206 1.3×	109 1.2×	119 2.2×	45 0.9×	52 2.5×	19	297
Gladice Wallraven United States	6	88 0.6×	63 0.7×	58 1.1×	11 0.2×	14 0.7×	11	134
Claudia Perne Germany	5	108 0.7×	56 0.6×	69 1.3×	5 0.1×	29 1.4×	10	170
Francisca Reyes Turcu United States	2	88 0.6×	23 0.3×	72 1.4×	31 0.6×	30 1.4×	2	140
Ashley Elrod France	2	132 0.9×	122 1.3×	99 1.9×	36 0.8×	64 3.0×	4	229
Jeff Isaacson United States	5	258 1.7×	50 0.5×	116 2.2×	99 2.1×	21 1.0×	8	284

Countries citing papers authored by Ernest Bognar

Since Specialization

Citations

This map shows the geographic impact of Ernest Bognar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernest Bognar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernest Bognar more than expected).

Fields of papers citing papers by Ernest Bognar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernest Bognar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernest Bognar. The network helps show where Ernest Bognar may publish in the future.

Co-authorship network of co-authors of Ernest Bognar

This figure shows the co-authorship network connecting the top 25 collaborators of Ernest Bognar. A scholar is included among the top collaborators of Ernest Bognar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernest Bognar. Ernest Bognar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Willoughby, David, Ernest Bognar, Laura Stanbery, et al.. (2025). Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product. Scientific Reports. 15(1). 8637–8637. 1 indexed citations

Sonavane, Manoj, Min Tang, John Nemunaitis, et al.. (2024). Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer. Gynecologic Oncology. 192. 65–72.

Anderson, Peter M., Brian D. Crompton, Kelly Klega, et al.. (2023). Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clinical Cancer Research. 29(9). 1689–1697. 15 indexed citations

Moon, Seongjun, Do Hoon Kim, Xiuquan Luo, et al.. (2023). A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells. Advanced NanoBiomed Research. 3(8). 2 indexed citations

Nemunaitis, John, Laura Stanbery, David Willoughby, et al.. (2023). Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response. Cancers. 15(23). 5616–5616. 4 indexed citations

Moon, Seongjun, Do Hoon Kim, Xiuquan Luo, et al.. (2023). A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells. SHILAP Revista de lepidopterología. 3(8). 1 indexed citations

Rocconi, Rodney P., Laura Stanbery, Min Tang, et al.. (2022). ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. SHILAP Revista de lepidopterología. 2(1). 106–106. 8 indexed citations

Barve, Minal, Phylicia Aaron, Luisa Manning, et al.. (2022). Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights Oncology. 16. 1363231461–1363231461. 15 indexed citations

Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 161(3). 676–680. 26 indexed citations

10.

Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 163(3). 459–464. 14 indexed citations

11.

Adams, Ned, Laura Stanbery, Luisa Manning, et al.. (2021). Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines. 9(10). 1201–1201. 6 indexed citations

12.

Morand, Susan, Khalil Choucair, David Willoughby, et al.. (2021). Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. Cancer Gene Therapy. 29(7). 993–1000. 5 indexed citations

13.

Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2021). Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Therapy. 29(3-4). 369–382. 20 indexed citations

14.

Rocconi, Rodney P., Laura Stanbery, Luciana Madeira da Silva, et al.. (2021). Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines. 9(8). 894–894. 12 indexed citations

15.

Rocconi, Rodney P., Sharad Ghamande, Minal Barve, et al.. (2021). Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.. Journal of Clinical Oncology. 39(15_suppl). 5502–5502. 4 indexed citations

16.

Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2020). A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. Journal of Clinical Oncology. 38(15_suppl). 3002–3002. 10 indexed citations

17.

Rocconi, Rodney P., Elizabeth A. Grosen, Sharad Ghamande, et al.. (2020). Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. Journal of Clinical Oncology. 38(15_suppl). 6017–6017. 3 indexed citations

18.

Oh, Jonathan, Minal Barve, Neil Senzer, et al.. (2020). Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. Gynecologic Oncology Reports. 34. 100648–100648. 19 indexed citations

19.

Rocconi, Rodney P., John K. Chan, Minal Barve, et al.. (2020). Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. Gynecologic Oncology. 159. 51–52. 3 indexed citations

20.

Manning, Luisa, Minal Barve, Gladice Wallraven, et al.. (2017). Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors. 2(1). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact